Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 16;10:4748. doi: 10.1038/s41598-020-61727-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Crosstalk between the Wnt/β-catenin and NF-κB pathways. (a) Immunoblotting analysis of the expression of β-TrCP in PC9 and PC9/ER cells cotreated with AG-205 (1 μM) plus erlotinib (20 nM). Data are means ± SD (n = 3); (One-Way ANOVA followed by Tukey correction). (b) Immunoblotting analysis of the expression levels of β-TrCP and IκBα in cells cotreated with XAV939 (10 μM) plus erlotinib (20 nM) for 72 h and 30 min, respectively. Data are means ± SD (n = 3); *P < 0.05 (One-Way ANOVA followed by Tukey correction). (c) Immunoblotting analysis of the expression of β-catenin in cells cotreated with JSH-23 (10 μM) and erlotinib (20 nM). Data are means ± SD (n = 3); *P < 0.05 (One-Way ANOVA followed by Tukey correction). N.S; not significant. (d,e) WST-8 assay of the effects of combination treatment of erlotinib and (d) MG-132 or (e) GS-143 on cell viability. Data are means ± SD (n = 3); **P < 0.01, ^†P < 0.05, ^††P < 0.01 vs. PC9/ER cells treated with erlotinib alone, ^‡‡P < 0.01 vs. PC9 cells treated with erlotinib alone (Two-Way ANOVA followed by Bonferroni correction); N.S; not significant.